Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation

Biomaterials

Volumn 35, Issue 29, 2014, Pages 8385-8393

  Wang, Qian ^a   Tan, Melody T ^b   Keegan, Brian P ^a   Barry, Meagan A ^a   Heffernan, Michael J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Rice University   (United States)

Author keywords

Drug delivery; Immunostimulation; Microsphere; Poly(lactic co glycolic acid) (PLGA); Vaccine

Indexed keywords

ANTIBODIES; ANTIGENS; CONTROLLED DRUG DELIVERY; DRUG DELIVERY; KINETICS; MAMMALS; MICROSPHERES; TARGETED DRUG DELIVERY; VACCINES;

IMMUNE RESPONSE; IMMUNOSTIMULATION; KINETICS STUDIES; POLY(LACTIC-CO-GLYCOLIC ACID); PROTECTIVE IMMUNITIES; PROTEIN ANTIGENS; TOLL-LIKE RECEPTORS; VACCINE DELIVERY SYSTEM;

IMMUNE SYSTEM;

ALUMINUM HYDROXIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B; INTERLEUKIN 4; POLYGLACTIN; CPG-OLIGONUCLEOTIDE; DRUG CARRIER; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LACTIC ACID; OLIGODEOXYRIBONUCLEOTIDE; OVALBUMIN; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHEMICAL COMPOSITION; CONTROLLED STUDY; CPG ISLAND; CYTOKINE RELEASE; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MEMORY CELL; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; IMMUNOLOGY; VACCINATION;

MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LACTIC ACID; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; POLYGLYCOLIC ACID; VACCINATION; VACCINES;

EID: 84904114652     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.067     Document Type: Article

References (53)

1. O'Hagan D.T., De Gregorio E. The path to a successful vaccine adjuvant - 'The long and winding road'. Drug Discov Today 2009, 14:541-551.
2. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
3. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11:S63-S68.
4. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22:411-416.
5. De Temmerman M.L., Rejman J., Demeester J., Irvine D.J., Gander B., De Smedt S.C. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 2011, 16:569-582.
6. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10:499-511.
7. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61:248-255.
8. ClinicalTrials.gov website, U.S. National Institutes of Health. Accessed 2014 February. Available from:, Search term: "CpG7909". http://clinicaltrials.gov.
9. Jaafari M.R., Badiee A., Khamesipour A., Samiei A., Soroush D., Kheiri M.T., et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007, 25:6107-6117.
10. + T cell responses and protection against Leishmania major infection. JExp Med 2002, 195:1565-1573.
11. +-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 2005, 73:6017-6025.
12. + T cells. Vaccine 2007, 25:6018-6027.
13. + CTL and B cell-mediated cross-priming. JImmunol 2007, 179:6889-6900.
14. Giddings O.K., Eickhoff C.S., Sullivan N.L., Hoft D.F. Intranasal vaccinations with the trans-sialidase antigen plus CpG adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges. Infect Immun 2010, 78:1333-1338.
15. Kumar S., Jones T.R., Oakley M.S., Zheng H., Kuppusamy S.P., Taye A., et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 2004, 72:949-957.
16. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6:797-808.
17. Diwan M., Elamanchili P., Cao M., Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr Drug Deliv 2004, 1:405-412.
18. Diwan M., Tafaghodi M., Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. JControl Release 2002, 85:247-262.
19. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26:1626-1637.
20. Malyala P., Chesko J., Ugozzoli M., Goodsell A., Zhou F., Vajdy M., et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. JPharm Sci 2008, 97:1155-1164.
21. Tafaghodi M., Khamesipour A., Jaafari M.R. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol Res 2011, 108:1265-1273.
22. Hamdy S., Haddadi A., Hung R.W., Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011, 63:943-955.
23. Hoshino K., Kaisho T. Nucleic acid sensing Toll-like receptors in dendritic cells. Curr Opin Immunol 2008, 20:408-413.
24. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7:179-190.
25. Kawai T., Akira S. Toll-like receptor and RIG-1-like receptor signaling. Ann N Y Acad Sci 2008, 1143:1-20.
26. Cassidy W.M., Watson B., Ioli V.A., Williams K., Bird S., West D.J. Arandomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 2001, 107:626-631.
27. Ekstrom N., Ahman H., Verho J., Jokinen J., Vakevainen M., Kilpi T., et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 2005, 73:369-377.
28. Siegrist C.-A. Vaccine immunology. Vaccines 2008, 17-36. Elsevier, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
29. Dalmia N., Ramsay A.J. Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines 2012, 11:1221-1233.
30. Brice G.T., Dobano C., Sedegah M., Stefaniak M., Graber N.L., Campo J.J., et al. Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes Infect 2007, 9:1439-1446.
31. Griffin J.F., Mackintosh C.G., Rodgers C.R. Factors influencing the protective efficacy of a BCG homologous prime-boost vaccination regime against tuberculosis. Vaccine 2006, 24:835-845.
32. + T-cell memory. Nat Rev Immunol 2008, 8:107-119.
33. Mueller M., Schlosser E., Gander B., Groettrup M. Tumor eradication by immunotherapy with biodegradable PLGA microspheres - an alternative to incomplete Freund's adjuvant. Int J Cancer 2011, 129:407-416.
34. Demento S.L., Cui W., Criscione J.M., Stern E., Tulipan J., Kaech S.M., et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012, 33:4957-4964.
35. Wilson H.L., Kovacs-Nolan J., Latimer L., Buchanan R., Gomis S., Babiuk L., et al. Anovel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection. Vaccine 2010, 28:8288-8299.
36. Heit A., Schmitz F., Haas T., Busch D.H., Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol 2007, 37:2063-2074.
37. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
38. Patel M.M., Zeles M.G., Manning M.C., Randolph T.W., Anchordoquy T.J. Degradation kinetics of high molecular weight poly(L-lactide) microspheres and release mechanism of lipid:DNA complexes. JPharm Sci 2004, 93:2573-2584.
39. Sah H. Anew strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres. JPharm Sci 1997, 86:1315-1318.
40. Frey A., Di Canzio J., Zurakowski D. Astatistically defined endpoint titer determination method for immunoassays. JImmunol Methods 1998, 221:35-41.
41. H2-related disease. JAllergy Clin Immunol 2014, 133:189-197.
42. Kheradmand F., Kiss A., Xu J., Lee S.H., Kolattukudy P.E., Corry D.B. Aprotease-activated pathway underlying Th cell type 2 activation and allergic lung disease. JImmunol 2002, 169:5904-5911.
43. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., O'Hagan D.T. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. JControl Release 2006, 110:566-573.
44. Meyer J.D., Manning M.C. Hydrophobic ion pairing: altering the solubility properties of biomolecules. Pharm Res 1998, 15:188-193.
45. 14C-labeled tetanus toxoid. Vaccine 1996, 14:1412-1416.
46. Huntimer L., Ramer-Tait A.E., Petersen L.K., Ross K.A., Walz K.A., Wang C., et al. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery. Adv Healthc Mater 2013, 2:369-378.
47. Arvand M., Ignatius R., Regnath T., Hahn H., Mielke M.E. Bartonella henselae-specific cell-mediated immune responses display a predominantly Th1 phenotype in experimentally infected C57BL/6 mice. Infect Immun 2001, 69:6427-6433.
48. Hamm S., Heit A., Koffler M., Huster K.M., Akira S., Busch D.H., et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response invivo. Int Immunol 2007, 19:297-304.
49. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-293.
50. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21:23-29.
51. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
52. Krishnamachari Y., Salem A.K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009, 61:205-217.
53. Ledgerwood J.E., Zephir K., Hu Z., Wei C.J., Chang L., Enama M.E., et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. JInfect Dis 2013, 208:418-422.